Reports world wide Polycystic Ovary Syndrome (PCOS)

Market Spotlight: Polycystic Ovary Syndrome (PCOS)
This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key
pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease
prevalence forecast, as well as licensing and acquisition deals.
Key Takeaways
Datamonitor Healthcare estimates that in 2016, there were approximately 112.2 million
(NIH criteria) to 186.9 million (Rotterdam criteria) prevalent cases of polycystic ovary
syndrome (PCOS) in females aged 15–49 years worldwide, and expects that number to
increase to 118.0 million (NIH criteria) to 196.6 million (Rotterdam criteria) by 2025.
The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and
follicle stimulating hormone receptor. These drugs are commonly administered via the oral
and subcutaneous routes, with one product being available in intramuscular formulation.
A majority of industry-sponsored drugs in active clinical development for PCOS are in Phase
II, with only one drug in Phase III. Therapies in pipeline for PCOS focus on targets such as
AMP-activated protein kinase and neurokinin receptor. All the pipeline drugs are
administered orally.
There was only one licensing agreement during 2012–17. The deal was an exclusive
licensing agreement between Millendo and AstraZeneca for the worldwide development and
commercialization rights to MLE4901.
The clinical trials distribution across Phase I–IV indicates that the majority of trials for PCOS
have been in Phases III–IV, with 87.6% of trials, and only 12.5% of trials in Phase II.
The US has a substantial lead in the number of PCOS clinical trials globally. Germany and
UK lead the major EU markets, while Indonesia and South Korea have the equal top spot in
Asia.
Clinical trial activity in the PCOS space is dominated by completed trials. Merck KGaA has
the highest number of completed clinical trials for PCOS, with five in total.
Merck KGaA leads industry sponsors with the highest number of clinical trials for PCOS,
followed by AstraZeneca and Merck & Co.
Exclusive Sample Report @
Major TOC Market:
1 KEY TAKEAWAYS
2 DISEASE BACKGROUND
3 TREATMENT
4 Clomiphene citrate
5 Gonadotropins
https://www.reportsworldwide.com/enquiry?report_id=42615